Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Fig. 2

Subgroup analyses of change in ePV through week 24. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CI confidence interval, DPP-4 dipeptidyl peptidase-4, eEV estimated extracellular volume, eGFR estimated glomerular filtration rate, ePV estimated plasma volume, HF heart failure, SBP systolic blood pressure, UACR urinary albumin-creatinine ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840